OQS
NPCE icon

Occudo Quantitative Strategies’s Neuropace NPCE Stock Holding History

Occudo Quantitative Strategies’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,873
Closed -$212K – 817
2025
Q1 		$212K Buy
+17,873
New +$224K 0.03% 550

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Occudo Quantitative Strategies's NPCE Position: Q2 2025 in Review

Occudo Quantitative Strategies sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 17,873 shares — an estimated $212K sold.

Occudo Quantitative Strategies first reported a position in NPCE in Q1 2025 and held it in 1 quarter. The position peaked at $212K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

  • Occudo Quantitative Strategies reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 17,873 Neuropace shares in Q2 2025, an estimated $212K.
  • Occudo Quantitative Strategies first reported a position in Neuropace in Q1 2025 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Neuropace position peaked at $212K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.